Kenya - English - Pharmacy and Poisons Board

isoniazid - tablet - isoniazid 300mg - isoniazid

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isoniazid, quantity: 100 mg - tablet, uncoated - excipient ingredients: propyl hydroxybenzoate; colloidal anhydrous silica; wheat starch; calcium stearate; sodium benzoate; dextrin; microcrystalline cellulose; sodium starch glycollate; gelatin; maize starch; lactose monohydrate - indications as at 21 oct 1999 : treatment of pulmonary and extrapulmonary tuberculosis in combination with other antitubercular agents.

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 1 kg in 1 kg

Kenya - English - Pharmacy and Poisons Board

sanofi-aventis kenya p.o box 20337 - 00200 nairobi kenya - rifampicin 150mg + isoniazid 75mg - tablet - rifampicin 150mg + isoniazid 75mg - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

sandoz private limited sandoz house, dr.annie besant road, worli, - rifampicin isoniazid pyrazinamide ethambutol… - film-coated tablet - rifampicin 150mg isoniazid 75mg pyrazinamide… - antimycobacterials: combinations of drugs for

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - isoniazid; pyrazinamide; rifampicin - tablet - 50 /300 /120 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin, pyrazinamide and isoniazid

Australia - English - Department of Health (Therapeutic Goods Administration)

isoniazid -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rph pharmaceuticals ab - isoniazid - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rifampicin; isoniazid - oral tablet - 300mg ; 150mg

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l), pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - rifampin 120 mg - rifater is indicated in the initial phase of the short-course treatment of pulmonary tuberculosis. during this phase, which should last 2 months, rifater should be administered on a daily, continuous basis (see dosage and administration). following the initial phase and treatment with rifater, treatment should be continued with rifampin and isoniazid (e.g., rifamate) for at least 4 months. treatment should be continued for a longer period of time if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to r